{"id":"detemir-or-glargine","safety":{"commonSideEffects":[{"rate":"variable, dose-dependent","effect":"Hypoglycemia"},{"rate":"common","effect":"Weight gain"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"rare","effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both are recombinant human insulin analogs designed for once or twice daily dosing in diabetes management. Detemir has a 16-carbon fatty acid chain that binds to albumin, providing a prolonged duration of action (up to 24 hours). Glargine forms microprecipitates in subcutaneous tissue that slowly release insulin, providing a relatively flat, long-acting profile (up to 24 hours or longer depending on formulation).","oneSentence":"Detemir and Glargine are long-acting basal insulin analogs that bind to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:33.336Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT05922033","phase":"PHASE4","title":"Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2023-10-19","conditions":"Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk","enrollment":56},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT06419777","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT02967224","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulins in Insulin Naïve Patients Initiating Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":705},{"nctId":"NCT02967211","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulin in Patients Already Using Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12-21","conditions":"Diabetes Mellitus, Type 2","enrollment":609},{"nctId":"NCT02922179","phase":"","title":"Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics","status":"COMPLETED","sponsor":"Biologics & Biosimilars Collective Intelligence Consortium","startDate":"2011-01-01","conditions":"Diabetes","enrollment":103951},{"nctId":"NCT04965051","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08","conditions":"Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range","enrollment":40},{"nctId":"NCT03001323","phase":"NA","title":"Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis","status":"TERMINATED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2017-01","conditions":"Diabetes Mellitus","enrollment":27},{"nctId":"NCT02846233","phase":"NA","title":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT04034524","phase":"","title":"Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2019-05-01","conditions":"Diabetes Mellitus, Type 2","enrollment":20000},{"nctId":"NCT02556918","phase":"PHASE4","title":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Hyperglycemia","enrollment":202},{"nctId":"NCT02824510","phase":"NA","title":"Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2014-08","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT02451137","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-16","conditions":"Diabetes Mellitus, Type 2","enrollment":3304},{"nctId":"NCT03960814","phase":"","title":"A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-21","conditions":"Diabetes Mellitus, Type 2","enrollment":12847},{"nctId":"NCT01850615","phase":"PHASE3","title":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":323},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000},{"nctId":"NCT03908762","phase":"NA","title":"mHealth Titration and Management","status":"UNKNOWN","sponsor":"Amalgam Rx, Inc.","startDate":"2019-01-01","conditions":"Diabetes Mellitus, Type 2, Diabetic Complication","enrollment":40},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT02741687","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-06","conditions":"Hyperglycemia","enrollment":80},{"nctId":"NCT02302716","phase":"PHASE3","title":"A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12","conditions":"Diabetes Mellitus, Type 2","enrollment":493},{"nctId":"NCT03180281","phase":"NA","title":"Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2017-07-01","conditions":"Type 2 Diabetes Mellitus","enrollment":135},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT01497535","phase":"PHASE1","title":"Within-subject Variability of Insulin Detemir in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-05-27","conditions":"Diabetes, Healthy","enrollment":40},{"nctId":"NCT00283751","phase":"PHASE3","title":"Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":583},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02360254","phase":"","title":"Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Padova","startDate":"2015-01","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT00467649","phase":"PHASE4","title":"A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02204839","phase":"NA","title":"Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM","status":"COMPLETED","sponsor":"Northumbria University","startDate":"2014-01","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT01011868","phase":"PHASE2","title":"Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":494},{"nctId":"NCT00862875","phase":"PHASE4","title":"Levemir-Body Composition and Energy Metabolism","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2009-03","conditions":"Type 2 Diabetes","enrollment":42},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT01271517","phase":"PHASE4","title":"Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2005-09","conditions":"Diabetes Mellitus Type 1","enrollment":120},{"nctId":"NCT00764556","phase":"PHASE2","title":"Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2008-05","conditions":"COPD, Hyperglycemia","enrollment":20},{"nctId":"NCT00405418","phase":"PHASE4","title":"Lantus Versus Levemir Treat-To-Target","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-11","conditions":"Diabetes Mellitus, Type 2","enrollment":973}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4070,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Detemir","Levemir","Long acting insulin","Bed time insulin","Lantus"],"phase":"marketed","status":"active","brandName":"Detemir or Glargine","genericName":"Detemir or Glargine","companyName":"Institut de Recherches Cliniques de Montreal","companyId":"institut-de-recherches-cliniques-de-montreal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Detemir and Glargine are long-acting basal insulin analogs that bind to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}